Inhibikase Therapeutics IncNASDAQ:IKT
- LAST PRICE2.6100
- TODAY'S CHANGE (%)-0.0300 (-1.1364%)
- Bid / Lots2.4800/ 6
- Ask / Lots2.6500/ 7
- Open / Previous Close2.6200 / 2.6400
- Day Range
- 52 Week Range
- Volume166,365
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IKT |
|---|---|---|
| 09:32 ET | 1505 | 2.62 |
| 09:33 ET | 4020 | 2.6299 |
| 09:35 ET | 1681 | 2.6 |
| 09:37 ET | 2100 | 2.5704 |
| 09:39 ET | 2100 | 2.56 |
| 09:42 ET | 1075 | 2.513 |
| 09:44 ET | 1000 | 2.5374 |
| 09:46 ET | 4291 | 2.53 |
| 09:51 ET | 1579 | 2.54 |
| 09:53 ET | 634 | 2.5001 |
| 09:55 ET | 14884 | 2.455 |
| 10:02 ET | 3000 | 2.5227 |
| 10:06 ET | 2000 | 2.5599 |
| 10:08 ET | 2989 | 2.52 |
| 10:11 ET | 1000 | 2.53 |
| 10:15 ET | 5124 | 2.55 |
| 10:18 ET | 300 | 2.56 |
| 10:27 ET | 200 | 2.5375 |
| 10:38 ET | 100 | 2.57 |
| 10:42 ET | 1591 | 2.535 |
| 10:51 ET | 5000 | 2.5227 |
| 10:58 ET | 100 | 2.54 |
| 11:00 ET | 100 | 2.525 |
| 11:02 ET | 7245 | 2.555 |
| 11:12 ET | 2972 | 2.5501 |
| 11:16 ET | 600 | 2.55 |
| 11:20 ET | 1000 | 2.575 |
| 11:21 ET | 3500 | 2.588234 |
| 11:27 ET | 1300 | 2.62 |
| 11:30 ET | 2213 | 2.625 |
| 11:32 ET | 4800 | 2.6 |
| 11:34 ET | 6400 | 2.61 |
| 11:36 ET | 3000 | 2.59 |
| 11:38 ET | 1208 | 2.56 |
| 11:41 ET | 200 | 2.55 |
| 11:43 ET | 2952 | 2.54 |
| 11:52 ET | 100 | 2.54 |
| 11:56 ET | 200 | 2.53 |
| 11:57 ET | 1000 | 2.57 |
| 11:59 ET | 300 | 2.53 |
| 12:19 ET | 1040 | 2.5999 |
| 12:26 ET | 100 | 2.59 |
| 12:30 ET | 200 | 2.58 |
| 12:33 ET | 527 | 2.6 |
| 12:46 ET | 1200 | 2.645 |
| 12:53 ET | 3258 | 2.645 |
| 12:55 ET | 1175 | 2.645 |
| 12:57 ET | 100 | 2.68 |
| 01:00 ET | 100 | 2.68 |
| 01:04 ET | 100 | 2.665 |
| 01:09 ET | 2981 | 2.7083 |
| 01:13 ET | 1049 | 2.75 |
| 01:15 ET | 7693 | 2.71 |
| 01:22 ET | 410 | 2.74 |
| 01:26 ET | 100 | 2.735 |
| 01:27 ET | 3116 | 2.66 |
| 01:42 ET | 100 | 2.62 |
| 01:47 ET | 2100 | 2.62 |
| 01:51 ET | 100 | 2.62 |
| 01:54 ET | 400 | 2.63 |
| 02:03 ET | 600 | 2.6 |
| 02:12 ET | 400 | 2.56 |
| 02:16 ET | 1850 | 2.62 |
| 02:20 ET | 200 | 2.5901 |
| 02:23 ET | 439 | 2.61 |
| 02:30 ET | 1915 | 2.61 |
| 02:38 ET | 300 | 2.61 |
| 02:45 ET | 100 | 2.61 |
| 02:48 ET | 230 | 2.605 |
| 02:59 ET | 500 | 2.595 |
| 03:03 ET | 1793 | 2.615 |
| 03:12 ET | 100 | 2.64 |
| 03:14 ET | 100 | 2.64 |
| 03:17 ET | 9785 | 2.65 |
| 03:19 ET | 900 | 2.63 |
| 03:21 ET | 507 | 2.63 |
| 03:30 ET | 100 | 2.62 |
| 03:33 ET | 100 | 2.62 |
| 03:35 ET | 400 | 2.61 |
| 03:37 ET | 100 | 2.61 |
| 03:42 ET | 100 | 2.61 |
| 03:46 ET | 112 | 2.6027 |
| 03:48 ET | 300 | 2.61 |
| 03:50 ET | 100 | 2.62 |
| 03:51 ET | 100 | 2.62 |
| 03:53 ET | 200 | 2.63 |
| 03:55 ET | 100 | 2.62 |
| 03:57 ET | 500 | 2.62 |
| 04:00 ET | 2078 | 2.61 |
Oct 21, 2024
Oct 14, 2024
DJ Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 1:32PM ET on Monday Oct 14, 2024 by Dow Jones
1:32PM ET on Monday Oct 14, 2024 by Dow Jones
Oct 9, 2024
*DJ Inhibikase Therapeutics: Directors Gisele Dion and Paul Grint Will Resign From Board and 4 New Directors Will Join, from 9:21AM ET on Wednesday Oct 09, 2024 by Dow Jones
9:21AM ET on Wednesday Oct 09, 2024 by Dow JonesInhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension, from 9:18AM ET on Wednesday Oct 09, 2024 by Dow Jones
9:18AM ET on Wednesday Oct 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibikase Therapeutics Inc | 173.6M | -0.9x | --- |
Immutep Ltd | 263.2M | -7.9x | --- |
Acumen Pharmaceuticals Inc | 170.9M | -2.6x | --- |
Greenwich Lifesciences Inc | 176.7M | -16.5x | --- |
Context Therapeutics Inc | 170.2M | -2.1x | --- |
Candel Therapeutics Inc | 169.4M | -3.1x | --- |
Company Information
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
Contact Information
- Headquarters
- 3350 Riverwood Parkway Se, Suite 1900ATLANTA, GA, United States 30339
- Phone
- 678-392-3419
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Roberto Bellini
- President, Chief Executive Officer, Director
- Milton Werner
- Chief Financial Officer
- Garth Lees-Rolfe
- Director
- David Canner
- Director
- Arvind Kush
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $173.6M |
|---|---|
Revenue (TTM) | $79.6K |
Shares Outstanding | 65.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-2.93 |
Book Value | $1.77 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 2,182.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -23,885.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
